{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:33:15Z","timestamp":1773275595757,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T00:00:00Z","timestamp":1292371200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/bf03347067","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T12:41:52Z","timestamp":1396442512000},"page":"201-205","source":"Crossref","is-referenced-by-count":12,"title":["A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves\u2019 disease: Need to retarget the radiation committed dose to the thyroid"],"prefix":"10.1007","volume":"34","author":[{"given":"M.","family":"Schiavo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Bagnara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Calamia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bossert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ceresola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pilot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,15]]},"reference":[{"key":"BF03347067_CR1","first-page":"624","volume":"21","author":"S Hertz","year":"1942","unstructured":"Hertz S, Roberts A. Application of radioactive iodine in therapy of Graves\u2019 disease. J Clin Invest 1942, 21: 624 (abstract).","journal-title":"J Clin Invest"},{"key":"BF03347067_CR2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/thy.1997.7.163","volume":"7","author":"CT Sawin","year":"1997","unstructured":"Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid 1997, 7: 163\u201376.","journal-title":"Thyroid"},{"key":"BF03347067_CR3","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1210\/jc.2003-031223","volume":"89","author":"CH Read Jr","year":"2004","unstructured":"Read CH Jr, Tansey M Jr, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves\u2019 patients. J Clin Endocrinol Metab 2004, 89: 4229\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03347067_CR4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/BF03344157","volume":"29","author":"B Tarantini","year":"2006","unstructured":"Tarantini B, Ciuoli C, Di Cairano G, et al. Effectiveness of radioiodine (131|) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism. J Endocrinol Invest 2006, 29: 594\u20138.","journal-title":"J Endocrinol Invest"},{"key":"BF03347067_CR5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-0029-1211072","volume":"97","author":"G D Wartofsky","year":"1991","unstructured":"Wartofsky, Glinoer D, Solomon B, Lagasse R. Differences and similarities in the treatment of diffuse goiter in Europe and the United States. Exp Clin Endocrinol 1991, 97: 243\u201351.","journal-title":"Exp Clin Endocrinol"},{"key":"BF03347067_CR6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Bogazzi F, et al. Relationship between therapy for hyperthyroidism and the course of ophthalmopathy. N Engl J Med 1998, 338: 73\u20138.","journal-title":"N Engl J Med"},{"key":"BF03347067_CR7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1055\/s-2003-41807","volume":"35","author":"N Gomez-Arnaiz","year":"2003","unstructured":"Gomez-Arnaiz N, Andia E, Gum\u00e0 A, et al. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131| treatment outcome in Graves\u2019 disease hyperthyroidism. Horm Metab Res 2003, 35: 492\u20137.","journal-title":"Horm Metab Res"},{"key":"BF03347067_CR8","first-page":"411","volume":"32","author":"RA Nordyke","year":"1991","unstructured":"Nordyke RA, Gilbert FI Jr. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves\u2019 disease. J Nucl Med 1991, 32: 411\u20136.","journal-title":"J Nucl Med"},{"key":"BF03347067_CR9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2265.1988.tb03683.x","volume":"28","author":"AB Watson","year":"1988","unstructured":"Watson AB, Brownlie BE, Frampton CM, et al. Outcome following standardized 185 MBq dose 131| therapy for Graves\u2019 disease. Clin Endocrinol (Oxf) 1988, 28: 487\u201396.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03347067_CR10","first-page":"1073","volume":"87","author":"EK Alexander","year":"2002","unstructured":"Alexander EK, Reed Larsen P. High dose 131| therapy for the treatment of hyperthyroidism caused by Graves\u2019 disease. J Clin Endocrinol Metab 2002, 87: 1073\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03347067_CR11","first-page":"3488","volume":"86","author":"VA Andrade","year":"2001","unstructured":"Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves\u2019 hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001, 86: 3488\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03347067_CR12","first-page":"3611","volume":"86","author":"A Allahabadia","year":"2001","unstructured":"Allahabadia A, Daykin J, Sheppard MC, et al. Radioiodine treatment of hyperthyroidism-Prognostic factors for outcome. J Clin Endocrinol Metab 2001, 86: 3611\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03347067_CR13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1385\/ENDO:25:1:55","volume":"25","author":"C Erem","year":"2004","unstructured":"Erem C, Kandemir N, Hacihasanoglu A, et al. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine 2004, 25: 55\u201360.","journal-title":"Endocrine"},{"key":"BF03347067_CR14","first-page":"40","volume":"83","author":"L Chiovato","year":"1998","unstructured":"Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves\u2019 patients treated with radioiodine: role of thyroid-stimulating and thyrotropin blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998, 83: 40\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03347067_CR15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF03348615","volume":"13","author":"C Marcocci","year":"1990","unstructured":"Marcocci C, Gianchecchi D, Masini I, et al. Areappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves\u2019 hyperthyroidism. J Endocrinol Invest 1990, 13: 513\u201320.","journal-title":"J Endocrinol Invest"},{"key":"BF03347067_CR16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF03345702","volume":"32","author":"C Regalbuto","year":"2009","unstructured":"Regalbuto C, Marturano A, Condorelli A, et al. Radiometabolic treatment of hyperthyroidism with a calculated dose of131|-iodine: results of one-year follow-up. J Endocrinol Invest 2009, 32: 134\u20138.","journal-title":"J Endocrinol Invest"},{"key":"BF03347067_CR17","unstructured":"Dottorini ME, IngleseE, Salvatori M, Signore A, Squatrito S, Vitti P. Linee Guida SIE-AIMN-AIFM 2005 \u201cIl trattamento radiometabolico dell\u2019ipertiroidismo\u201d 2005 ( www.aimn.it )."},{"key":"BF03347067_CR18","volume-title":"Report of a Working Party","author":"Royal College of Physicians.","year":"2007","unstructured":"Royal College of Physicians. Radioiodine in the management of benign thyroid disease-Clinical guidelines. Report of a Working Party. London: RCP, 2007 ( http:\/\/www.rcplondon.ac.uk\/Pages\/index.aspx )."},{"key":"BF03347067_CR19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1160\/nukmed-0288","volume":"46","author":"M Dietlein","year":"2007","unstructured":"Dietlein M, Dressler J, Gr\u00fcnwald F, et al. Guideline for radioiodine therapy for benign thyroid disease (version 4), Nuklearmedizin 2007, 46: 220\u20133.","journal-title":"Nuklearmedizin"},{"key":"BF03347067_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/oxfordjournals.rpd.a006531","volume":"95","author":"AC Traino","year":"2001","unstructured":"Traino AC, Di Martino F, Lazzeri M, Stabin MG. Study of the correlation between administered activity and radiation committed dose to the thyroid in 131| therapy of Graves\u2019 disease. Rad Prot Dosim 2001, 95: 117\u201324.","journal-title":"Rad Prot Dosim"},{"key":"BF03347067_CR21","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJM198911163212001","volume":"321","author":"L Bartalena","year":"1989","unstructured":"Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves\u2019 ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989, 321: 1403\u20135.","journal-title":"N Engl J Med"},{"key":"BF03347067_CR22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/BF03346299","volume":"30","author":"F Massaro","year":"2007","unstructured":"Massaro F, Vera L, Schiavo M, et al. Ultrasonography thyroid volume estimation in hyperthyroid patients treated with individual radioiodine dose. J Endocrinol Invest 2007, 30: 318\u201322.","journal-title":"J Endocrinol Invest"},{"key":"BF03347067_CR23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF01476194","volume":"1","author":"EB Sandell","year":"1937","unstructured":"Sandell EB, Kolthoff IM. Micro determination of iodine by a catalytic method. Mikrochemica Acta 1937, 1: 9\u201325.","journal-title":"Mikrochemica Acta"},{"key":"BF03347067_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Bogazzi F, et al. Relationship between therapy for hyperthyroidism and the course of Graves\u2019 ophtalmopathy. N Engl J Med 1998, 338: 73\u20138.","journal-title":"N Engl J Med"},{"key":"BF03347067_CR25","volume-title":"\u201cS\u201d, absorbed dose per unit cumulated activity for selected radionuclides and organs, MIRD Pamphlet No. 11","author":"W Snyder","year":"1975","unstructured":"Snyder W, Ford M, Warner G, Watson S. \u201cS\u201d, absorbed dose per unit cumulated activity for selected radionuclides and organs, MIRD Pamphlet No. 11. New York: Society of Nuclear Medicine, 1975."},{"key":"BF03347067_CR26","unstructured":"International Commission on Radiological Protection \u2014 ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals. Annals of the ICRP, Volume18\/1\u20134, Elsevier, 1988."},{"key":"BF03347067_CR27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/jc.2009-1655","volume":"95","author":"F Bogazzi","year":"2009","unstructured":"Bogazzi F, Giovanetti C, Fessehatsion R, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves\u2019 Disease: a cohort study on cure rate, time to cure and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab 2009, 95: 201\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03347067_CR28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MNM.0b013e328333d303","volume":"31","author":"C Kobe","year":"2010","unstructured":"Kobe C, Eschner W, Wild M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131|? Nucl Med Commun 2010, 31: 201\u20135.","journal-title":"Nucl Med Commun"},{"key":"BF03347067_CR29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/cncr.23124","volume":"112","author":"L Giovanella","year":"2008","unstructured":"Giovanella L. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2008, 112: 220.","journal-title":"Cancer"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03347067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03347067\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03347067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T04:50:13Z","timestamp":1565326213000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03347067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,15]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["BF03347067"],"URL":"https:\/\/doi.org\/10.1007\/bf03347067","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,15]]}}}